- Home
- AVNW vs DMAC Comparison
AVNW vs DMAC Comparison
Compare AVNW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNW
- DMAC
- Stock Information
- Founded
- AVNW 2006
- DMAC 2000
- Country
- AVNW United States
- DMAC United States
- Employees
- AVNW N/A
- DMAC N/A
- Industry
- AVNW Radio And Television Broadcasting And Communications Equipment
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- AVNW Technology
- DMAC Health Care
- Exchange
- AVNW Nasdaq
- DMAC Nasdaq
- Market Cap
- AVNW 274.4M
- DMAC 310.1M
- IPO Year
- AVNW 2007
- DMAC N/A
- Fundamental
- Price
- AVNW $24.38
- DMAC $6.79
- Analyst Decision
- AVNW Strong Buy
- DMAC Strong Buy
- Analyst Count
- AVNW 3
- DMAC 3
- Target Price
- AVNW $32.00
- DMAC $12.33
- AVG Volume (30 Days)
- AVNW 76.9K
- DMAC 256.1K
- Earning Date
- AVNW 11-04-2025
- DMAC 11-12-2025
- Dividend Yield
- AVNW N/A
- DMAC N/A
- EPS Growth
- AVNW N/A
- DMAC N/A
- EPS
- AVNW 0.10
- DMAC N/A
- Revenue
- AVNW $434,606,000.00
- DMAC N/A
- Revenue This Year
- AVNW $5.75
- DMAC N/A
- Revenue Next Year
- AVNW $6.82
- DMAC N/A
- P/E Ratio
- AVNW $243.80
- DMAC N/A
- Revenue Growth
- AVNW 6.50
- DMAC N/A
- 52 Week Low
- AVNW $12.96
- DMAC $3.19
- 52 Week High
- AVNW $26.83
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- AVNW 57.73
- DMAC 51.02
- Support Level
- AVNW $22.71
- DMAC $6.50
- Resistance Level
- AVNW $25.32
- DMAC $7.10
- Average True Range (ATR)
- AVNW 0.90
- DMAC 0.31
- MACD
- AVNW 0.21
- DMAC -0.03
- Stochastic Oscillator
- AVNW 78.14
- DMAC 43.03
About AVNW Aviat Networks Inc.
Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.